2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Han van den Bosch

Session 4 – Combating Pandemics (A)
Date: 22 July (Wednesday) 14:00 – 15:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Han van den Bosch

Professor
Vaxilon 
(on behalf of Medigen Vaccine Biologics Corp., Taiwan)


 

Han van den Bosch is emeritus professor “International Public Health” at the Free University in Amsterdam. Furthermore, he is active as partner and consultant for several Biotech companies and Global Health organizations.

He holds degrees in Biology and Medical Microbiology, and specialized in vaccinology. His professional career involved both academic positions as well as executive R&D management positions in pharmaceutical companies such as Intervet, Nobilon, Schering-Plough and Merck.

Furthermore, he has been involved in an advisory role with several national and international organizations active in vaccine development and Global Health.


Speech title & Synopsis

Vaccine Development During the COVID-19 Pandemic

In case of a pandemic, vaccines are considered to be the cornerstone of the containment strategy guidelines in the WHO Health Regulations (2005). In the global search for a vaccine against COVID-19, Taiwan’s Medigen Vaccine Biologics Corp. (MVC) has joined the efforts for rapid vaccine development with a world class technology. For an effective vaccine, the highly immunogenic SARS-CoV2 Spike pre-fusion trimer protein as designed by the NIH-NIAID in the USA, will be produced in cell-culture. This protein subunit vaccine is being formulated with the strong T-cell immunity driven adjuvant CpG1018 from DYNAVAX, an adjuvant that is approved for use in a Hepatitis-B vaccine in the USA. After very promising early pre-clinical animal studies with the prototype vaccine, current vaccine development work is aiming for entering the first-in-human Phase I clinical trial in the autumn of this year. If successful, further clinical trials may continue during 2021, leading up to potential emergency use approval. Aligned with the clinical development, the production process will be optimized and scaled up to sufficient doses in order to allow for vaccination campaigns in both Taiwan and the region, by early 2022. Although this development time if successful would be at an unprecedented speed, the high importance of rapid availability of an effective vaccine is eminent. Since the COVID-19 is currently endemic all over the world, only vaccination will probably give sufficient immunity among the population in order to allow for the return to a normal life.
​​